Because PD-L1-negative EpCAM+ cancer cells, low PD-1 expressed CD8+T cells, and remarkably increased CD14+CD68+CD163+TIM-3+ macrophages were observed in MPE with disease progression (Figure 1), TIM-3 blockade therapy might be applicable to treatment [31]. The gene discussed is HAVCR2; the disease is cancer.